Alicia Augustine is the Associate Director for Research in the Center for Human Experimental Therapeutics (CHET) and a Research Assistant Professor in the Department of Community and Preventive Medicine. CHET carries out the mission of conducting hypothesis-driven, rigorously designed, initial investigations of novel therapeutic interventions for human diseases, and is the T1 Key Function within the Clinical and Translational Science Institute. In her role as Associate Director, Dr. Augustine is responsible for collaborative initiation and maintenance of research projects within CHET, as well as engaging with University of Rochester investigators regarding research design and implementation of early phase clinical studies. Additional responsibilities include representation of CHET within the Clinical and Translational Science Institute and co-coordination/instruction of the Experimental Therapeutics course (PM488). Her primary research interests include pre-clinical experimentation and early-phase trial design.

• Clementi AH, Gaudy AM, Zimmers TA, Koniaris LG, Mooney RA. Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse. Metabolism. 2011 Nov; 60(11):1610-9.
  View in: PubMed
• Gaudy AM, Clementi AH, Campbell JS, Smrcka AV, Mooney RA. Suppressor of cytokine signaling-3 is a glucagon-inducible inhibitor of PKA activity and gluconeogenic gene expression in hepatocytes. J Biol Chem. 2010 Dec 31; 285(53):41356-65.
  View in: PubMed
• Clementi AH, Gaudy AM, van Rooijen N, Pierce RH, Mooney RA. Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochim Biophys Acta. 2009 Nov; 1792(11):1062-72.
  View in: PubMed
• Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 2005 Aug; 146(8):3417-27.
  View in: PubMed